IBDEI0J7 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8640,1,3,0)
 ;;=3^Diseases of Blood/Blood-Forming Organs,Other Spec
 ;;^UTILITY(U,$J,358.3,8640,1,4,0)
 ;;=4^D75.89
 ;;^UTILITY(U,$J,358.3,8640,2)
 ;;=^5002392
 ;;^UTILITY(U,$J,358.3,8641,0)
 ;;=D47.Z9^^39^401^182
 ;;^UTILITY(U,$J,358.3,8641,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8641,1,3,0)
 ;;=3^Neop Lymphoid,Hematopoietic & Related Tissue,Uncertain Behavior,Other
 ;;^UTILITY(U,$J,358.3,8641,1,4,0)
 ;;=4^D47.Z9
 ;;^UTILITY(U,$J,358.3,8641,2)
 ;;=^5002262
 ;;^UTILITY(U,$J,358.3,8642,0)
 ;;=D05.82^^39^401^39
 ;;^UTILITY(U,$J,358.3,8642,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8642,1,3,0)
 ;;=3^Carcinoma in Situ Left Breast,Other Spec Type
 ;;^UTILITY(U,$J,358.3,8642,1,4,0)
 ;;=4^D05.82
 ;;^UTILITY(U,$J,358.3,8642,2)
 ;;=^5001934
 ;;^UTILITY(U,$J,358.3,8643,0)
 ;;=D05.81^^39^401^41
 ;;^UTILITY(U,$J,358.3,8643,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8643,1,3,0)
 ;;=3^Carcinoma in Situ Right Breast,Oth Spec Type
 ;;^UTILITY(U,$J,358.3,8643,1,4,0)
 ;;=4^D05.81
 ;;^UTILITY(U,$J,358.3,8643,2)
 ;;=^5001933
 ;;^UTILITY(U,$J,358.3,8644,0)
 ;;=D05.80^^39^401^43
 ;;^UTILITY(U,$J,358.3,8644,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8644,1,3,0)
 ;;=3^Carcinoma in Situ Unspec Breast,Oth Spec Type
 ;;^UTILITY(U,$J,358.3,8644,1,4,0)
 ;;=4^D05.80
 ;;^UTILITY(U,$J,358.3,8644,2)
 ;;=^5001932
 ;;^UTILITY(U,$J,358.3,8645,0)
 ;;=D56.8^^39^401^205
 ;;^UTILITY(U,$J,358.3,8645,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8645,1,3,0)
 ;;=3^Thalassemias,Other
 ;;^UTILITY(U,$J,358.3,8645,1,4,0)
 ;;=4^D56.8
 ;;^UTILITY(U,$J,358.3,8645,2)
 ;;=^5002305
 ;;^UTILITY(U,$J,358.3,8646,0)
 ;;=C82.89^^39^401^81
 ;;^UTILITY(U,$J,358.3,8646,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8646,1,3,0)
 ;;=3^Follicular Lymphoma,Extranodal/Solid Organ Sites,Other Types
 ;;^UTILITY(U,$J,358.3,8646,1,4,0)
 ;;=4^C82.89
 ;;^UTILITY(U,$J,358.3,8646,2)
 ;;=^5001540
 ;;^UTILITY(U,$J,358.3,8647,0)
 ;;=D51.8^^39^401^212
 ;;^UTILITY(U,$J,358.3,8647,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8647,1,3,0)
 ;;=3^Vitamin B12 Deficiency Anemias,Other
 ;;^UTILITY(U,$J,358.3,8647,1,4,0)
 ;;=4^D51.8
 ;;^UTILITY(U,$J,358.3,8647,2)
 ;;=^5002288
 ;;^UTILITY(U,$J,358.3,8648,0)
 ;;=I80.9^^39^401^187
 ;;^UTILITY(U,$J,358.3,8648,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8648,1,3,0)
 ;;=3^Phlebitis/Thrombophlebitis,Unspec Site
 ;;^UTILITY(U,$J,358.3,8648,1,4,0)
 ;;=4^I80.9
 ;;^UTILITY(U,$J,358.3,8648,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,8649,0)
 ;;=D45.^^39^401^188
 ;;^UTILITY(U,$J,358.3,8649,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8649,1,3,0)
 ;;=3^Polycythemia Vera
 ;;^UTILITY(U,$J,358.3,8649,1,4,0)
 ;;=4^D45.
 ;;^UTILITY(U,$J,358.3,8649,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,8650,0)
 ;;=C77.3^^39^401^117
 ;;^UTILITY(U,$J,358.3,8650,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8650,1,3,0)
 ;;=3^Malig Neop Axilla/Upper Limb Lymph Nodes,Sec and Unspec
 ;;^UTILITY(U,$J,358.3,8650,1,4,0)
 ;;=4^C77.3
 ;;^UTILITY(U,$J,358.3,8650,2)
 ;;=^5001330
 ;;^UTILITY(U,$J,358.3,8651,0)
 ;;=C77.2^^39^401^133
 ;;^UTILITY(U,$J,358.3,8651,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8651,1,3,0)
 ;;=3^Malig Neop Intra-Abdominal Lymph Nodes,Sec and Unspec
 ;;^UTILITY(U,$J,358.3,8651,1,4,0)
 ;;=4^C77.2
 ;;^UTILITY(U,$J,358.3,8651,2)
 ;;=^267316
 ;;^UTILITY(U,$J,358.3,8652,0)
 ;;=C77.1^^39^401^134
 ;;^UTILITY(U,$J,358.3,8652,1,0)
 ;;=^358.31IA^4^2
